Valuation : Ionis Pharmaceuticals, Inc.

Market Cap 10.15B 8.74B 8.2B 7.49B 14.07B 965B 14.17B 97.19B 37.82B 490B 38.09B 37.27B 1,621B P/E 2026 *
-16.8x
P/E 2027 * -32.3x
Enterprise Value 10.04B 8.65B 8.12B 7.41B 13.92B 956B 14.02B 96.21B 37.43B 485B 37.71B 36.89B 1,604B EV / Sales 2026 *
11x
EV / Sales 2027 * 7.28x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -
1 day-1.33%
1 week-2.97%
Current month+16.28%
1 month+16.28%
3 months-20.14%
6 months-23.47%
Current year-23.90%
1 week 59.7
Extreme 59.7
64.19
1 month 52.16
Extreme 52.165
64.19
Current year 50
Extreme 50.005
86.74
1 year 49.13
Extreme 49.13
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/07/26 Buy

Director

5,000 0.0030%
15/07/26 Free

Director

3,399 0.0021%
15/07/26 Free

Director

3,399 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-1.44%-2.97%+4.71%+49.49% 10.15B
-1.23%-1.91%+0.98%+17.94% 50.47B
-1.91%-3.47%+416.67%+501.24% 44.56B
-0.40%-0.05%+41.57%+16.84% 43.08B
-2.45%-3.79%+7.78%+72.42% 41.7B
-0.94%-1.77%+18.34%+46.84% 33.21B
-1.92%-4.99%+24.46%+117.97% 16.77B
+6.68%+5.00% - - 16.28B
+0.25%-0.98%+11.63%+27.62% 14.58B
-1.50%-3.80%+78.13%+38.88% 13.92B
Average -0.46%-0.90%+67.14%+98.80% 28.47B
Weighted average by Cap. -0.85%-0.93%+85.89%+119.08%

Financials

2026 *2027 *
Net sales 913M 786M 738M 674M 1.27B 86.91B 1.28B 8.75B 3.4B 44.07B 3.43B 3.35B 146B 1.4B 1.21B 1.13B 1.03B 1.94B 133B 1.96B 13.43B 5.23B 67.64B 5.26B 5.15B 224B
Net income -602M -519M -487M -445M -835M -57.32B -841M -5.77B -2.25B -29.07B -2.26B -2.21B -96.24B -326M -281M -263M -240M -452M -31.01B -455M -3.12B -1.21B -15.72B -1.22B -1.2B -52.06B
Net Debt -103M -88.65M -83.24M -75.99M -143M -9.8B -144M -986M -384M -4.97B -387M -378M -16.45B 57.45M 49.47M 46.45M 42.4M 79.65M 5.47B 80.22M 550M 214M 2.77B 216M 211M 9.18B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
31/08/26 $60.20 -1.39% 786,813
28/08/26 $61.05 -2.21% 1,850,852
27/08/26 $62.43 -1.47% 1,625,581
26/08/26 $63.36 -0.33% 2,152,847
25/08/26 $63.57 +2.47% 2,435,239
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
61.05USD
Average target price
88.00USD
Spread / Average Target
+44.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock